December 19, 2013, Consun Pharmaceutical Group Limited (“Consun Pharmaceutical”) successfully launched its initial public offering for a Hong Kong Stock Exchange main board listing under the stock code of 1681, raising approximately HKD 1 billion in total.

Consun Pharmaceutical is an integrated pharmaceutical company principally engaged in the research, manufacture and sale of modern Chinese medicines and medical contrast medium in the PRC.

Jingtian & Gongcheng acted as the issuer’s PRC legal counsel.